Stereotaxis Inc. (NYSEAMERICAN:STXS - Get Free Report) Director Arun Swarup Menawat bought 121,561 shares of the stock in a transaction dated Tuesday, November 17th. The shares were acquired at an average price of $0.82 per share, with a total value of $99,680.02. Following the completion of the acquisition, the director directly owned 1,157,121 shares of the company's stock, valued at approximately $948,839.22. The trade was a 11.74% increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.
Stereotaxis Stock Performance
Shares of STXS traded up $0.06 during mid-day trading on Wednesday, reaching $0.95. The company had a trading volume of 900,994 shares, compared to its average volume of 991,370. The firm has a 50-day moving average price of $1.10 and a 200 day moving average price of $1.61. Stereotaxis Inc. has a 52 week low of $0.80 and a 52 week high of $2.86. The company has a market capitalization of $94.80 million, a price-to-earnings ratio of -3.94 and a beta of 1.40.
Stereotaxis (NYSEAMERICAN:STXS - Get Free Report) last posted its quarterly earnings data on Tuesday, November 10th. The company reported ($0.07) earnings per share for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.02). The company had revenue of $8.93 million for the quarter, compared to the consensus estimate of $9.60 million. Stereotaxis had a negative net margin of 70.86% and a negative return on equity of 144.02%. As a group, research analysts forecast that Stereotaxis Inc. will post -0.22 earnings per share for the current fiscal year.
Analysts Set New Price Targets
A number of research firms have recently commented on STXS. Citigroup reissued an "outperform" rating on shares of Stereotaxis in a research note on Thursday, August 27th. Citizens Jmp lowered their price target on Stereotaxis from $4.00 to $3.00 and set a "market outperform" rating for the company in a research report on Thursday, August 27th. Finally, TD Cowen dropped their price target on shares of Stereotaxis from $3.00 to $2.00 and set a "buy" rating on the stock in a research note on Wednesday, November 11th. Four analysts have rated the stock with a Buy rating. Based on data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus price target of $2.83.
View Our Latest Report on STXS
Institutional Investors Weigh In On Stereotaxis
Institutional investors and hedge funds have recently made changes to their positions in the company. Goldman Sachs Group Inc. lifted its position in Stereotaxis by 40.2% in the 3rd quarter. Goldman Sachs Group Inc. now owns 329,420 shares of the company's stock valued at $405,000 after acquiring an additional 94,449 shares in the last quarter. Cetera Investment Advisers purchased a new stake in Stereotaxis during the 3rd quarter valued at $60,000. Empowered Funds LLC purchased a new stake in Stereotaxis during the 3rd quarter valued at $154,000. R Squared Ltd increased its holdings in shares of Stereotaxis by 262.7% in the 3rd quarter. R Squared Ltd now owns 49,784 shares of the company's stock worth $61,000 after purchasing an additional 36,057 shares in the last quarter. Finally, Integrity Alliance LLC. bought a new stake in shares of Stereotaxis in the 3rd quarter worth $860,000. Institutional investors own 45.35% of the company's stock.
Stereotaxis Company Profile
(
Get Free Report)
Stereotaxis develops robotic technologies for minimally invasive procedures, with a focus on treating heart rhythm disorders. Its systems are designed to help physicians guide catheters through blood vessels and within the heart during procedures such as cardiac ablation. The company's products include the Genesis Robotic Magnetic Navigation System, which uses externally controlled magnetic fields to steer compatible catheters, and the Odyssey platform for managing and displaying information in interventional procedure rooms.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Stereotaxis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Stereotaxis wasn't on the list.
While Stereotaxis currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.
Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.